RxDoctor Payments Data

Amanda Bazan

Family · Greenfield, INNPI 1205334448

Payments from drug & device makers

$1,552in general payments, 2019–2025

Across 104 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$361
  • Novo Nordisk$208
  • Lilly USA, LLC$125
  • Takeda Pharmaceuticals U.S.A., Inc.$77
  • GSK$72
  • Corium, LLC$68
  • plus $641 from 21 others

What the payments were for

  • Food & beverage$1,552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,552 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,183
EliquisApixaban12$7,123
Duloxetine Hcl21$927
Albuterol Sulfate HfaAlbuterol Sulfate42$820
Omeprazole42$739
Metoprolol Succinate32$403
Gabapentin29$372
Atorvastatin Calcium48$306
Bupropion XlBupropion Hcl15$289
Buspirone Hcl23$289
Losartan Potassium13$224
Fluticasone Propionate21$215
Tamsulosin Hcl25$213
Sertraline Hcl17$210
Lisinopril28$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$72$14,18320 claims
PfizerEliquis$43$7,12312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Greenfield

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →